Gene Therapy Market to 2018 - Product Development Slowed by Clinical Failures, Close Regulatory Surveillance and High Compliance Standards


June 25, 2012
76 Pages - SKU: XGBR3944315
License type:
Table of Contents Search inside this report Related Reports Detailed Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction /B>
3 Gene Therapy Market – Technology Overview /B>
3.1 Introduction
3.1.1 Gene
3.1.2 Genome
3.1.3 DNA
3.2 Genetic Disorders
3.3 Gene Therapy
3.3.1 Types of Gene Therapies
3.4 Need for Gene Therapy
3.5 Vectors Used in Gene Therapy
3.5.1 Viral Vectors
3.5.2 Non-Viral Vectors
3.6 Role of Gene Therapy in the Pharmaceutical Industry
3.6.1 Upstream Action of Gene Therapies Makes Them More Effective Than the Existing Biologic Therapies
4 Gene Therapy Market – Clinical Development Trends /B>
4.1 Gene Therapy Clinical Development by Year
4.2 Gene Therapy Clinical Development by Vectors Used
4.3 Gene Therapy Clinical Development by Geography
4.4 Gene Therapy Clinical Development by Therapy Area
5 Gene Therapy Market – Market Environment Characterization /B>
5.1 Market Drivers
5.1.1 Failure of Conventional Therapies to Treat Cancers and Other Indications has Created High Unmet Needs
5.1.2 Entry of Gene Therapies in Developed Nations Will Poise the Market Growth
5.1.3 Rising Incidence and Prevalence of Chronic and Life Threatening Diseases
5.1.4 Possible Treatment for Monogenic Conditions Can Give Access to Previously Undeveloped Markets
5.2 Market Restraints
5.2.1 Stringent Regulatory Laws Delay Gene Therapy Development
5.2.2 Safety Concerns
5.2.3 Technical Limitations in Present Technology
5.3 Market Analysis
5.3.1 Strengths
5.3.2 Weakness
5.3.3 Opportunities
5.3.4 Threats
5.4 Current Marketed Products
5.4.1 Gendicine
5.4.2 Oncorine
5.4.3 Rexin-G
6 Gene Therapy Market – Pipeline Analysis /B>
6.1 Research and Development Analysis
6.1.1 R&D Pipeline by Phase
6.1.2 R&D Pipeline by Therapy Area
6.2 Promising Molecules in the Pipeline
6.2.1 Collategene
6.2.2 Allovectin-7
6.2.3 Generx
6.3 Failed Late Stage Products
6.3.1 Glybera
6.3.2 Cerepro
6.3.3 NV1FGF
6.3.4 TNFerade
7 Gene Therapy Market – Regulatory Landscape /B>
7.1 Gene Therapy and the Regulatory Environment
7.1.1 The US
7.1.2 Europe
7.1.3 Japan
8 Gene Therapy Market – Competetive Landscape /B>
8.1 Profiles of Major Companies in Gene Therapy R&D
8.1.1 ReGenX Biosciences
8.1.2 Oxford BioMedica plc
8.1.3 EGEN
8.1.4 Sangamo BioSciences
8.1.5 BioSante Pharmaceuticals
8.1.6 Amsterdam Molecular Therapeutics (AMT)
8.2 Recent Deals in the Gene Therapy Market
8.2.1 MolMed Enters into an Agreement with Fondazione Telethon
8.2.2 GlaxoSmithKline Enters into Co-Development Agreement with McGill University
8.2.3 Amsterdam Molecular Therapeutics Enters into an Agreement with Institut Pasteur and the Consortium
8.2.4 Oxford BioMedica Enters into Research Agreement with Mayo Clinic
8.2.5 RetroSense Therapeutics Enters into Licensing Agreement with Wayne State University
8.2.6 Amsterdam Molecular Expands Licensing Agreement with National Institute of Health
8.2.7 GlaxoSmithKline Enters into Licensing Agreement with Fondazione Telethon
8.2.8 GlaxoSmithKline Enters into Strategic Alliance with Fondazione Telethon and Fondazione San Raffaele
8.2.9 Bluebird bio Enters into Licensing Agreement with INSERM
9 Gene Therapy Market – Appendix /B>
9.1 Abbreviations
9.2 Market Definitions
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Expert Panel Validation
9.3.5 Section-wise Research Methodology
9.4 Sources
9.5 Contact Us
9.6 Disclaimer
1.1 List of Tables
Table 1: Gene Therapy Market to 2018, Global, Gene Therapy Clinical Trials by Year, 1989–2011
Table 2: Gene Therapy Market to 2018, Global, Gene Therapy Clinical Trials by Type of Vector Used, 1989–2011
Table 3: Gene Therapy Market to 2018, Global, Gene Therapy Clinical Trials by Geography, 1989–2011
Table 4: Gene Therapy Market to 2018, Global, Gene Therapy Clinical Trials by Therapy Area, 1989–2011
Table 5: Gene Therapy Market to 2018, Gendicine Phase II/III Clinical Trials Results, 2005
Table 6: Gene Therapy Market to 2018, Global, Pipeline Projects by Phase, %, 2011
Table 7: Gene Therapy Market to 2018, Global, Phase III Pipeline Molecules, 2011
Table 8: Gene Therapy Market to 2018, Global, Phase II Pipeline Molecules, 2011
Table 9: Gene Therapy Market to 2018, Global, Phase I Pipeline Molecules, 2011
Table 10: Gene Therapy Market to 2018, Global, IND Filed Pipeline Molecules, 2011
Table 11: Gene Therapy Market to 2018, Global, Preclinical Pipeline Molecules, 2011
Table 12: Gene Therapy Market to 2018, Global, Discovery Pipeline Molecules, 2011
Table 13: Gene Therapy Market to 2018, Global, Pipeline Projects by Therapy Area, %, 2011
Table 14: Gene Therapy Market to 2018, Global, Oncology Pipeline Projects, 2011
Table 15: Gene Therapy Market to 2018, Global, Central Nervous System Pipeline Projects, 2011
Table 16: Gene Therapy Market to 2018, Global, Hematological Disorders Pipeline Projects, 2011
Table 17: Gene Therapy Market to 2018, Global, Ophthalmology Disorders Pipeline Projects, 2011
Table 18: Gene Therapy Market to 2018, Global, Companies with Gene Therapy Projects, 2011
1.2 List of Figures
Figure 1: Gene Therapy Market to 2018, Global, Gene Therapy Clinical Trials by Year, 1989–2011
Figure 2: Gene Therapy Market to 2018, Global, Gene Therapy Clinical Trials by Type of Vector Used, %, 1989–2011
Figure 3: Gene Therapy Market to 2018, Global, Gene Therapy Clinical Trials by Geography, %, 1989–2011
Figure 4: Gene Therapy Market to 2018, Global, Gene Therapy Clinical Trials by Therapy Area, %, 1989–2011
Figure 5: Gene Therapy Market to 2018, Global, Market Drivers and Restraints, 2011
Figure 6: Gene Therapy Market to 2018, Global, Cost vs. Unmet Needs Comparison of Key Drug Classes, 2011
Figure 7: Gene Therapy Market to 2018, Global, SWOT Analysis
Figure 8: Gene Therapy Market to 2018, Global, Pipeline Projects by Stage of Development, %, 2011
Figure 9: Gene Therapy Market to 2018, Global, Pipeline Projects by Therapy Area, %, 2011
Figure 10: Gene Therapy Market to 2018, Global, Oncology Pipeline Projects by Stage of Development, %, 2011
Figure 11: Gene Therapy Market to 2018, Global, Oncology Pipeline Projects by Indication, %, 2011
Figure 12: Gene Therapy Market to 2018, Global, Central Nervous System Pipeline Projects by Stage of Development, %, 2011
Figure 13: Gene Therapy Market to 2018, Global, Central Nervous System Pipeline Projects by Indication, %, 2011
Figure 14: Gene Therapy Market to 2018, Global, Hematological Disorders Pipeline Projects by Stage of Development, %, 2011
Figure 15: Gene Therapy Market to 2018, Global, Hematological Disorders Pipeline Projects by Indication, %, 2011
Figure 16: Gene Therapy Market to 2018, Global, Ophthalmology Disorders Pipeline Projects by Stage of Development, %, 2011
Figure 17: Gene Therapy Market to 2018, Global, Ophthalmology Disorders Pipeline Projects by Indication, %, 2011
Figure 18: Gene Therapy Market to 2018, Global, Companies with Gene Therapy Projects in the Pipeline, %, 2011
Figure 19: ReGenX Biosciences, SWOT Analysis, 2012
Figure 20: Oxford BioMedica, SWOT Analysis, 2012
Figure 21: EGEN, SWOT Analysis, 2012
Figure 22: Sangamo BioSciences, SWOT Analysis, 2012
Figure 23: BioSante Pharmaceuticals, SWOT Analysis, 2012
Figure 24: Amsterdam Molecular Therapeutics, SWOT Analysis, 2012
 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Related Markets

Gene Therapy Reports
 
 

Share this report


Other tasks

 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!